Get the Stockscreener App
1.38
2.82%
-0.04
Evotec Se Adr stock is traded at $1.38, with a volume of 82,403.
It is down -2.82% in the last 24 hours and down -15.34% over the past month.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
See More
Previous Close:
$1.42
Open:
$1.43
24h Volume:
82,403
Relative Volume:
0.58
Market Cap:
$490.44M
Revenue:
$863.66M
Net Income/Loss:
$-225.27M
P/E Ratio:
-2.176
EPS:
-0.6342
Net Cash Flow:
$-63.28M
1W Performance:
-9.80%
1M Performance:
-15.34%
6M Performance:
-57.14%
1Y Performance:
-65.50%
1-Day Range:
$1.38
$1.43
1-Week Range:
$1.33
$1.48
52-Week Range:
$1.33
$4.27
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
1.38 | 490.44M | 863.66M | -225.27M | -63.28M | -0.6342 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-26 | Downgrade | Berenberg | Buy → Hold |
| Jul-15-26 | Downgrade | TD Cowen | Buy → Hold |
| Apr-15-26 | Resumed | H.C. Wainwright | Buy |
| Feb-03-26 | Initiated | Berenberg | Buy |
| Apr-24-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Oct-07-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jul-29-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-11-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-08-23 | Upgrade | Citigroup | Neutral → Buy |
| Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-10-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Jan-07-22 | Resumed | Citigroup | Neutral |
View All
Evotec Se Adr Stock (EVO) Latest News
A €2.5109-per-share block trade ends an investment in Evotec SE (EVO). - Stock Titan
BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne - GlobeNewswire Inc.
Evotec SE (NASDAQ: EVO) Initiates First Human Trial for JST-018 Under 2023 Accelerated Antibodies Contract - Kalkine Media
Evotec starts Phase 1 trial for JST-018 antibody therapy - grafa.com
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
EVO Q2 2026 Earnings: Sharply Narrower $0.26 per-ADS Loss Beats Forecast, Yet Stock Falls 4.26%Earnings Manipulation Risk - dars.gov.et
EVO Q2 2026 Earnings: Sharply Narrower $0.26 per-ADS Loss Beats Forecast, Yet Stock Falls 4.26%Cash Flow Report - dars.gov.et
Evotec SE (EVO) Rebounds 2.12% as Shares Approach Key $2.03 ResistanceFloat Adjusted Cap - dars.gov.et
Evotec SE (EVO) Rebounds 2.12% as Shares Approach Key $2.03 ResistanceDaily Profile - careplusvn.com
EVO Q1 2026 Earnings: Wider-than-Expected Loss Despite Stock RiseNet Income Trends - dars.gov.et
Evotec SE (EVO) Rebounds 2.12% as Shares Approach Key $2.03 ResistanceLast Point Resistance - dars.gov.et
EVO Q1 2026 Earnings: Wider-than-Expected Loss Despite Stock RiseSurprise Factor Analysis - www.dars.gov.et
Evotec stock struggles after profit warning as Q2 2026 figures and guidance cuts weigh on sentiment - ad-hoc-news.de
Evotec (EVO) Quarterly Figures: The Available Earnings Metric Delivers a Miss for the Current Session; Closing Reaction: The Stock Loses 1.53% in Latest TradingPre-Earnings Setup - dars.gov.et
Evotec stock trades close to 52-week low as Q2 revenue declines - ad-hoc-news.de
Evotec (EVO) Momentum: Loses 3.03% to Close at $1.92 in Latest Trading; Chart Watch: Price Remains Between $1.82 Support and $2.02 Resistance for the Current SessionMomentum ETF - dars.gov.et
Evotec (EVO) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Response: The Stock Ends Up 3.66% in the Latest ReadingProfit Cycle Analysis - careplusvn.com
Evotec (EVO) Earnings Snapshot: The EPS Result Is Below Expectation in the Latest Session; Stock Move: The Market Price Declines 3.03% in Latest TradingAnalyst Drop Coverage - careplusvn.com
Evotec (EVO) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Response: The Stock Ends Up 3.66% in the Latest ReadingEarnings Season Review - dars.gov.et
Evotec (EVO) Momentum: Loses 3.03% to Close at $1.92 in Latest Trading; Chart Watch: Price Remains Between $1.82 Support and $2.02 Resistance for the Current SessionLow Volume Node - www.dars.gov.et
Evotec (EVO) Momentum: Loses 3.03% to Close at $1.92 in Latest Trading; Chart Watch: Price Remains Between $1.82 Support and $2.02 Resistance for the Current SessionScalping Stock Signals - www.dars.gov.et
Evotec (EVO) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Response: The Stock Ends Up 3.66% in the Latest ReadingReturn On Assets - www.dars.gov.et
Evotec stock trades at a discount to recent analyst targets as Xetra shares retreat - ad-hoc-news.de
Evotec stock trades well below analyst targets as selling pressure intensifies - Ad-hoc-news.de
Evotec stock faces earnings estimate cut as ADR trades below $2 - ad-hoc-news.de
Evotec (EVO) Earnings Brief: EPS Comes in Below Forecast on the Day; Market Follow-Through: Shares Move 2.55% DownEarnings Cycle Report - dars.gov.et
Evotec (EVO) Earnings Brief: EPS Comes in Below Forecast on the Day; Market Follow-Through: Shares Move 2.55% DownEstimate Revision Count - dars.gov.et
Evotec AG Earnings Call: Weak 2026, Pipeline Hopes - The Globe and Mail
Evotec stock weakens after Q2 2026 miss and guidance cut - AD HOC NEWS
Evotec SE (EVO) Rebounds 4% to $2.08 as Drug Discovery Sector StabilizesETF NAV Deviation - careplusvn.com
Evotec signs AI drug discovery partnership with Odyssey - grafa.com
Evotec SE (EVO) Holds Near $1.95 as Shares Consolidate Above Key SupportFactor ETF Flow - dars.gov.et
Evotec SE (EVO) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesPost-Earnings Reaction - vinanet.vn
Evotec SE (EVO) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesSaaS Earnings Trends - dars.gov.et
Berenberg cuts Evotec on delayed pharma deals clouding revenue outlook - Investing.com
Berenberg cuts Evotec stock rating on guidance downgrade By Investing.com - Investing.com Nigeria
Berenberg cuts Evotec stock rating on guidance downgrade - Investing.com
Berenberg cuts Evotec stock rating on guidance downgrade By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
TD Cowen cuts Evotec on customer delays clouding growth outlook By Investing.com - Investing.com Nigeria
TD Cowen cuts Evotec on customer delays clouding growth outlook - Investing.com
H.C. Wainwright cuts Evotec stock price target on revenue guidance reduction - Investing.com
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
TD Cowen cuts Evotec stock rating on revenue delays, lowers target to $2 - Investing.com Nigeria
TD Cowen cuts Evotec stock rating on revenue delays, lowers target to $2 - Investing.com
TD Cowen cuts Evotec stock rating on revenue delays, lowers target to $2 - Investing.com Canada
Evotec (EVO) Slips Over 6% as Shares Test Key Support at $1.91Weak Sell Signals - careplusvn.com
Evotec (EVO) Slips Over 6% as Shares Test Key Support at $1.91Gap Up Stocks - dars.gov.et
Evotec (EVO) Slips Over 6% as Shares Test Key Support at $1.91Standard Deviation - www.dars.gov.et
Earnings call transcript: Evotec cuts 2026 outlook as Q2 revenue falls - Investing.com Nigeria
Evotec Se Adr Stock (EVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):